Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | TYMS | P04818 | 5/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 3/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CDC25A | P30304 | 1/20 | 0.36 |
| ▸ | CDC25C | P30307 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719830 | 0.83 | PARP1 (0.42) | PARP1TYMSLMNACDC25ACDC25C | |
| SCHEMBL1720496 | 0.80 | PARP1 (0.45) | PARP1TYMSCHEK1LMNASMN1; SMN2 | |
| SCHEMBL1721012 | 0.79 | PIM1 (0.46) | PARP1TYMSPIM1PIM2GAA | |
| SCHEMBL1720184 | 0.74 | PIM1 (0.47) | PARP1PIM1PIM2LMNASMN1; SMN2 | |
| SCHEMBL4075097 | 0.71 | PARP1 (0.46) | PARP1TYMSCHEK1PIM1PIM2 | |
| SCHEMBL1719755 | 0.70 | MAPK8 (0.48) | PARP1TYMSCHEK1PIM1HTR3A | |
| SCHEMBL10229093 | 0.68 | PARP1 (0.58) | PARP1TYMSCHEK1PIM1PIM2 | |
| SCHEMBL10222167 | 0.68 | CYP2A6 (0.40) | CHEK1PIM1PIM2LMNATP53 | |
| SCHEMBL1549073 | 0.65 | TNKS2 (0.67) | PARP1DAO | |
| SCHEMBL6519310 | 0.65 | AURKA (0.70) | PARP1TYMSCDC25ACDC25CDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | PARP1 1/4885TYMS 1123/4885CHEK1 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.